CA2323733A1 - Compositions vaccinales comprenant des antigenes cd-1 et un compose de stimulation des cellules t, et procedes d'utilisation desdites compositions - Google Patents

Compositions vaccinales comprenant des antigenes cd-1 et un compose de stimulation des cellules t, et procedes d'utilisation desdites compositions Download PDF

Info

Publication number
CA2323733A1
CA2323733A1 CA002323733A CA2323733A CA2323733A1 CA 2323733 A1 CA2323733 A1 CA 2323733A1 CA 002323733 A CA002323733 A CA 002323733A CA 2323733 A CA2323733 A CA 2323733A CA 2323733 A1 CA2323733 A1 CA 2323733A1
Authority
CA
Canada
Prior art keywords
antigen
response
composition
lipid
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002323733A
Other languages
English (en)
Inventor
Michael B. Brenner
Christopher C. Dascher
Steven A. Porcelli
Kenji Hiromatsu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Brigham and Womens Hospital Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2323733A1 publication Critical patent/CA2323733A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention concerne des compositions immunogènes ou vaccinales comprenant un antigène CD1 ou lipidique et un composé de stimulation des cellules T (p. ex. un adjuvant). L'invention concerne également des procédés d'administration desdites compositions immunogènes ou vaccinales.
CA002323733A 1998-04-13 1999-04-13 Compositions vaccinales comprenant des antigenes cd-1 et un compose de stimulation des cellules t, et procedes d'utilisation desdites compositions Abandoned CA2323733A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8163898P 1998-04-13 1998-04-13
US60/081,638 1998-04-13
PCT/US1999/008112 WO1999052547A1 (fr) 1998-04-13 1999-04-13 Compositions vaccinales comprenant des antigenes cd-1 et un compose de stimulation des cellules t, et procedes d'utilisation desdites compositions

Publications (1)

Publication Number Publication Date
CA2323733A1 true CA2323733A1 (fr) 1999-10-21

Family

ID=22165411

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002323733A Abandoned CA2323733A1 (fr) 1998-04-13 1999-04-13 Compositions vaccinales comprenant des antigenes cd-1 et un compose de stimulation des cellules t, et procedes d'utilisation desdites compositions

Country Status (5)

Country Link
EP (1) EP1071452A1 (fr)
JP (1) JP2002511421A (fr)
AU (1) AU3558899A (fr)
CA (1) CA2323733A1 (fr)
WO (1) WO1999052547A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020033366A1 (fr) 2018-08-08 2020-02-13 Nantbio, Inc. Lymphocytes t restreints à cd1 recombinés et méthodes

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPP675898A0 (en) * 1998-10-27 1998-11-19 Walter And Eliza Hall Institute Of Medical Research, The A method of activating t cells and agents useful for same
FR2792205B1 (fr) * 1999-04-19 2001-07-27 Inst Nat Sante Rech Med Composition pharmaceutique comprenant des cellules nkt activees par des pim, et son utilisation en therapie
EP1335741A4 (fr) * 2000-08-25 2005-10-26 Yeda Res & Dev Procedes de traitement ou de prevention de maladies auto-immunes au moyen d'un polynucleotide renfermant du cpg
GB0106987D0 (en) * 2001-03-20 2001-05-09 Stanford Rook Ltd Immunotherapeuitic agent
US7253159B2 (en) 2003-04-18 2007-08-07 The Brigham And Women's Hospital, Inc. Methods and compositions for immunomodulation using CD1 antigens
CA2662164A1 (fr) 2006-09-01 2008-03-06 Stirling John Edwards Procede visant a provoquer ou a induire une reponse immunitaire
EP1938836A1 (fr) * 2006-12-28 2008-07-02 Universite Rene Descartes (Paris V) Compositions comprenant une sous-unité B de la toxine dysentérique et moyen de stimulation des cellules NKT
EP2047860A1 (fr) * 2007-10-12 2009-04-15 Centre National De La Recherche Scientifique (Cnrs) Compositions pharmaceutiques comprenant des antigènes dérivés de glycérol acyle d'actinomycètes, leur procédé d'extraction et leur utilisation contre la tuberculose
JP2011500514A (ja) 2007-10-12 2011-01-06 シーエスエル、リミテッド 汎発流行性インフルエンザウィルスに対する免疫応答を惹起する方法
WO2010140377A1 (fr) * 2009-06-04 2010-12-09 独立行政法人産業技術総合研究所 Vaccin contre une infection par un mycoplasme
KR20200055135A (ko) * 2017-10-05 2020-05-20 난트셀, 인크. 지질계 항원 및 nk 세포상의 t-세포 수용체 (lipid-based antigens and t-cell receptors on nk cells)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10510142A (ja) * 1994-10-13 1998-10-06 ブリガム アンド ウイミンズ ホスピタル Ｃｄ１分子によるｔ細胞に対する疎水性抗原の提示
WO1998039025A2 (fr) * 1997-03-03 1998-09-11 Adcock Ingram Limited Composition renfermant un porteur et un composant lipidique membranaire mycobacterien purifie, son utilisation dans la prevention, le traitement et le diagnostic de maladies
AU749218C (en) * 1997-09-12 2003-10-30 Brigham And Women's Hospital Synthetic antigens for CD1-restricted immune responses

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020033366A1 (fr) 2018-08-08 2020-02-13 Nantbio, Inc. Lymphocytes t restreints à cd1 recombinés et méthodes

Also Published As

Publication number Publication date
JP2002511421A (ja) 2002-04-16
WO1999052547A1 (fr) 1999-10-21
AU3558899A (en) 1999-11-01
WO1999052547A9 (fr) 2000-03-02
EP1071452A1 (fr) 2001-01-31

Similar Documents

Publication Publication Date Title
Ouaissi et al. The Trypanosoma cruzi Tc52-released protein induces human dendritic cell maturation, signals via Toll-like receptor 2, and confers protection against lethal infection
US7122577B1 (en) Composition comprising a carrier and a purified mycobacterial lipid cell-wall component and its use in the treatment and diagnosis of disease
Williamson et al. Modulating dendritic cells to optimize mucosal immunization protocols
Enioutina et al. TLR-induced local metabolism of vitamin D3 plays an important role in the diversification of adaptive immune responses
US7001601B1 (en) Ganglioside-KLH conjugate vaccine plus QS-21
WO1996017614A1 (fr) Antigenes cellulaires inclus dans un adjuvant: conjugaison et procedes
Luci et al. Dendritic cell-mediated induction of mucosal cytotoxic responses following intravaginal immunization with the nontoxic B subunit of cholera toxin
TR201807756T4 (tr) Sentetik adjuvan içeren aşı bileşimi.
US20120321669A1 (en) Antigenic compositions
Xin et al. Immunization of RANTES expression plasmid with a DNA vaccine enhances HIV-1-specific immunity
EP1071452A1 (fr) Compositions vaccinales comprenant des antigenes cd-1 et un compose de stimulation des cellules t, et procedes d'utilisation desdites compositions
Kallert et al. Liposomal delivery of lipoarabinomannan triggers Mycobacterium tuberculosis specific T-cells
AU2002301229B2 (en) Synthetic Antigens for CD1-restricted Immune Responses
US20080248094A1 (en) Vaccine adjuvant properties of lipsomes formed at elevated temperatures from the polar chloroform extractable lipids from mycobacterium bovis
Waag Immune response to Coxiella burnetii infection
US20020044951A1 (en) Isolated and purified nonpeptide antigens from mycobacterium tuberculosis
Guthrie et al. Local and systemic antibody responses in mice immunized intranasally with native and detergent-extracted outer membrane vesicles from Neisseria meningitidis
EP0786088B1 (fr) Presentation d'antigenes de lipoarabinomannane a des lymphocytes t par des molecules cd1
WO1996012190A9 (fr) Presentation d'antigenes hydrophobes a des lymphocytes t par des molecules cd1
US7608246B2 (en) Apolipoprotein E as an adjuvant for lipid antigens
Fast et al. The muramyl dipeptide analog GMTP-N-DPG preferentially induces cellular immunity to soluble antigens
Abdol et al. Potent T-cell mediated immune response against Legionella pneumophila in mice following vaccination with detoxified lipopolysaccharide non-covalently combined with recombinant flagellin A and peptidoglycan-associated lipoprotein
Moura et al. Effect of Mycobacterium leprae lipids on BCG-and carrageenan-induced cellular recruitment in mouse pleurisy
Lee et al. Gene immunization for the induction of antigen-specific, non MHC-restricted responses
Holmgren et al. Dendritic Cell-Mediated Induction of

Legal Events

Date Code Title Description
FZDE Discontinued